EMBRACA Trial in HER2 Metastatic Breast Cancer
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial that compares the efficacy and safety of talazoparib (TA... Author: obr Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2019 Category: Cancer & Oncology Source Type: podcasts

KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us histhoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanc... Author: obr Added: 06/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2019 Category: Cancer & Oncology Source Type: podcasts

MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Scott Koenig discusses the data on the Phase 3 SOPHIA study.About MacroGenics, Inc.MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative mo... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin In HER2+ mEGA
David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin... Author: obr Added: 02/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2019 Category: Cancer & Oncology Source Type: podcasts

HER2 Mutation Positive NSCLC [720p]
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin. Author: cancergrace Added: 10/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 11, 2018 Category: Cancer & Oncology Source Type: podcasts

PI3-Kinase Inhibitors Do Not Work in Tumor Agnostic Way | Targeted Therapeutics Toward HER2 Do Not Always Work
Edward L. Nelson, MD, UC Irvine Health talk about PI3-Kinase Inhibitors Do Not Work in Tumor Agnostic Way | Targeted Therapeutics Toward HER2 Do Not Always Work at MOASC 2018 Author: moasc Added: 08/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2018 Category: Cancer & Oncology Source Type: podcasts

The MONALEESA-3 study in HR+/HER2- advanced breast cancer
Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer Author: obr Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 28, 2018 Category: Cancer & Oncology Source Type: podcasts

the PERSEPHONE trial in early HER2+ breast cancer
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting Author: obr Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 28, 2018 Category: Cancer & Oncology Source Type: podcasts

The MONALEESA-3 study in HR+/HER2- advanced breast cancer
Neelima Denduluri, MD, discusses the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer Author: obr Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

MONALEESA-3 study in HR+/HER2- advanced breast cancer
Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONAL... Author: obr Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is uncertain. The PERSEPHONE trial (ISRCTN52968807) looked at the efficac... Author: VJOncology Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

Results of the TAILORx study are practice changing
Sara M. Tolaney, MD, MPH, talks about whether the results of the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients are practice changing at ASCO 2018. Author: obr Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts

The TAILORx study
Sara M. Tolaney, MD, MPH, talks about the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means endocrine therapy alone is similar in efficacy to chemoendoc... Author: obr Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Outcomes of the MONARCH 2 study
Sara M. Tolaney, MD, MPH shares the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients at ASCO 2018. Author: obr Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Will Immunotherapy Be a PANACEA for Breast Cancer?
Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC. (Source: Medscape Oncology)
Source: Medscape Oncology - January 2, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab. (Source: Medscape Oncology)
Source: Medscape Oncology - December 29, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

HER2 Over Expressed in 60 percent of NSCLC
Joshua Bauml, MD of the University of Pennsylvania discusses the fact that HER2 is over expressed in 60 percent of NSCLC from the 22nd Annual Perspectives in Thoracic Oncology in New York http://imede...... Author: thoraciconcology Added: 12/28/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 28, 2017 Category: Cancer & Oncology Source Type: podcasts

Debate: Are novel targets such as HER2 ready for prime time in colorectal cancer? - No
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that the utilization of novel targets such as HER2 are not ready for prime time in the t... Author: imedex Added: 09/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - September 7, 2017 Category: Cancer & Oncology Source Type: podcasts

Neratinib and Capecitabine for Patients with HER2+ Breast Cancer Brain Metastases (BCBM)
Daniela Bota, MD of UC Irvine Health discusses the use of neratinib and capecitabine in patients with breast cancer brain metastases at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beac... Author: moasc Added: 08/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2017 Category: Cancer & Oncology Source Type: podcasts

PALOMA-1: Palbociclib in Combination with Letrozole versus Letrozole Alone in Breast Cancer
Rita Mehta, MD of UC Irvine Health gives an overview of the PALOMA-1 trial and the use of palbociclib and letrozole in the treatment of ER+ and HER2-advanced breast cancer. This was recorded at the 20... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

OlympiAD: Olaparib versus Chemotherapy in HER2-Negative Metastatic Breast Cancer and a Germline BRCA Mutation
Rita Mehta, MD of UC Irvine Health gives an overview of the OlympiAD study, which focuses on the use of olaparib in HER2 negative metastatic breast cancer. This was recorded at the 2017 MOASC Spotligh... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

MONARCH 2: Abemaciclib with Fulvestrant in HR+/HER2-Positive Early Breast Cancer
Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib with fulvestrant in patients with HR+/HER2- Advanced Breast Cancer who have progressed on endocrine therapy.... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

MONARCH 2: Abemaciclib with Fulvestrant in HR+/HER2 Negative Advanced Breast Cancer
Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib and fulvestrant in advanced HR+/HER2 negative breast cancer progressing patients following prior endocrine t... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

APHINITY: Pertuzumab as Adjuvant Therapy in HER2-Positive Early Breast Cancer
Rita Mehta, MD of UC Irvine Health gives an overview of the APHINITY trial and the use of pertuzumab as adjuvant therapy for patients with HER2+ early breast cancer. This was recorded at the 2017 MOAS... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

Targeting HER2, BRAF, KRAS, MET, TRK
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Evan W. Alley discusses the targeting of HER2, BRAF, KRAS, MET, and TRK mutations.Earn CME Credit for a related act... Author: imedex Added: 07/11/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 11, 2017 Category: Cancer & Oncology Source Type: podcasts

Potential ASCO Practice-Changers in HER2+ Breast Cancer
Oncologists will debate the APHINITY trial data for years to come, says Dr Kevin Kalinsky. (Source: Medscape Oncology)
Source: Medscape Oncology - July 7, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Importance of Early Molecular Testing in Colon Cancer
Howard S. Hochster, MD of Yale School of Medicine discusses the importance of recommending molecular testing early on to patients with colon cancer. He further explains the significance of HER2 testin... Author: GiDebates2017 Added: 06/01/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 2, 2017 Category: Cancer & Oncology Source Type: podcasts

Molecular Subtyping/Profiling and Update in HER2 Targeted Therapy
Yelena Yuriy Janjigian, MD, Memorial Sloan-Kettering gives an overview of her presentation, Molecular Subtyping/Profiling and Update in HER2 Targeted Therapy, which was discussed at the 2017 Great Deb... Author: GiDebates2017 Added: 05/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Use of HER2, BRAF, and Immunotherapy in Clinical Practice
Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains how to integrate HER2, BRAF, and immunotherapy into clinical practice. This was recorded at the 2017 Great Debates and Updates in GI Malignancie... Author: GiDebates2017 Added: 05/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2017 Category: Cancer & Oncology Source Type: podcasts

Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, Targets
In this presentation from the 14th Annual Best of San Antonio - Breast Cancer: Bench to Bedside, Dr. Debu Tripathy discusses novel therapeutics for the treatment of breast cancer, with a focus on HER2... Author: imedex Added: 04/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 25, 2017 Category: Cancer & Oncology Source Type: podcasts

Phase Ib Trial Evaluating T-DMI with Neratinib in Women with Metastatic HER2+ Breast Cancer
Jame Abraham, MD of Cleveland Clinic gives an overview of his abstract, NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic... Author: aacr2017 Added: 04/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 18, 2017 Category: Cancer & Oncology Source Type: podcasts

Breast Cancer 2016: The Lancet: December 6, 2016
Sibylle Loibl discusses recent advances in the treatment of oestrogen receptor positive, HER2-positive, and triple-negative breast cancers. (Source: Listen to The Lancet)
Source: Listen to The Lancet - December 8, 2016 Category: General Medicine Authors: The Lancet Source Type: podcasts

Bonanza of New Options for HR+/HER2- Breast Cancer
Patients with advanced HR-positive/HER2-negative breast cancer may benefit from practice-changing treatment options, as reported by Dr Javier Cort é s from ESMO 2016. (Source: Medscape Oncology)
Source: Medscape Oncology - October 19, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Targeting HER 2 and angiogenesis in gastric cancer: What is the impact?
In this presentation from the ESMO 18th World Congress on Gastrointestinal Cancer, Dr. Andrs Cervantes discusses the impact of targeting HER2 and angiogenesis in gastric cancer. Author: imedex Added: 08/19/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 19, 2016 Category: Cancer & Oncology Source Type: podcasts

ONT-380 for HER2+ metastatic breast cancer: promising results for patients with brain metastases
Erika Hamilton of Sarah Cannon Research Institute, Nashville, TN talks about a Phase I trial of ONT-380 in combination with capecitabine and T-DM1 (trastuzumab emtansine), in patients with HER2+ metas... Author: VJOncology Added: 08/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 18, 2016 Category: Cancer & Oncology Source Type: podcasts

Kimberly L. Blackwell, MD - Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - August 11, 2016 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Extreme Rare Mutations in Lung Cancer (ROS1, TRK, HER2): Treatment opportunities
In this presentation from the "17th Annual Congress: Perspectives in Lung Cancer", Dr. Lucio Crinò discusses extreme rare mutations in lung cancer (ROS1, TRK, HER2) and the treatment opportunities av... Author: imedex Added: 05/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 23, 2016 Category: Cancer & Oncology Source Type: podcasts

HER2 Mutation Positive NSCLC
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin. http://cancergrace.org/lung...... Author: cancergrace Added: 02/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2016 Category: Cancer & Oncology Source Type: podcasts

Targeting HER2, BRAF, KRAS, MET
The 20th Annual Perspectives in Thoracic Oncology, held in New York, NY from November 21-22, 2015 provided thoracic oncology clinicians and researchers with the latest information on the complex biolo... Author: imedex Added: 02/08/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 8, 2016 Category: Cancer & Oncology Source Type: podcasts

ToGA trial and how it changed the management of HER2+ gastric carcinoma ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses the ToGA trial and how it changed the management of HER2+ gastric carcinoma at ASCO GI 2016 Author: ASCOGI2016 Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts

ASCO GI 2016: How did the ToGA trial changed the management of HER2+ gastric carcinoma
Joel Randolph Hecht, MD of UCLA Health discusses how did the ToGA trial changed the management of HER2+ gastric carcinoma at ASCO GI 2016 Author: ASCOGI2016 Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2016 Category: Cancer & Oncology Source Type: podcasts

@OncEd Presents Dr. Wendie Den Brok - Survival of Metastatic HR Positive/HER2 Negative, Triple Negative and HER2 Positive Breast Cancer - Best of Oncology West 2015
Author: oncologyeducation Added: 12/02/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 2, 2015 Category: Cancer & Oncology Source Type: podcasts

Dr. Hamilton on Fox & Friends Discussing New HER2+ Breast Cancer Treatment - Sarah Cannon
Dr. Hamilton appeared on Fox & Friends to discuss a new treatment option for HER2+ breast cancer, an aggressive form of breast cancer that can spread to the brain. Author: SarahCannon Added: 09/17/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 17, 2015 Category: Cancer & Oncology Source Type: podcasts

Tools and Resources for Improving Neoadjuvant Therapy Decision-making for HER2+ Breast Cancer
Oncologists have indicated that favorable data is not the only factor to consider in their treatment decisions related to use of HER2-targeted neoadjuvant therapy (NAC) in breast cancer. Rather, the d... Author: imedex Added: 08/28/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2015 Category: Cancer & Oncology Source Type: podcasts

Strategies for Improving Neoadjuvant Therapy Decision-making for HER2+ Breast Cancer
Oncologists have indicated that favorable data is not the only factor to consider in their treatment decisions related to use of HER2-targeted neoadjuvant therapy (NAC) in breast cancer. Rather, the d... Author: imedex Added: 08/28/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2015 Category: Cancer & Oncology Source Type: podcasts

Neoadjuvant Pertuzumab in HER2-Positive Breast Cancer with Dr. Yee
Dr. Yee discusses the research that led to the FDA approval of neoadjuvant pertuzumab as part of a combination regimen for patients with HER2-positive breast cancer. Douglas Yee, MD, professor of med... Author: onclivetv Added: 08/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2015 Category: Cancer & Oncology Source Type: podcasts

Impact of Recent Data on Guidelines for Management of HER2-positive Breast Cancer
Filmed on location in Las Vegas during the 21st Annual NOCR Meeting, this webcast is part of a series that provides expert discussions from physicians and researchers from around the USA reviewing cur... Author: imedex Added: 08/06/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2015 Category: Cancer & Oncology Source Type: podcasts